Semaglutide 2 mg GLP-1 analogue peptide – diabetes, weight loss research


Available on backorder


Semaglutide 2 mg lyophilized

all peptides ship in unlabeled vials, with color coded cap for batch identification

Semaglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents. There have been no published reports of hepatotoxicity attributed to semaglutide therapy.

Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.

The primary focus of GLP-1 research has been in the realm of diabetes treatment/prevention as well as appetite suppression. Secondary research focuses on the potential cardiovascular benefits of the peptide. More recent, and thus less robust, research focuses on the ability of GLP-1 to stave off neurodegenerative disease. Though this latter area of research is newest, it is also the fast-growing area of GLP-1 study now that the peptide has been revealed to slow or prevent the accumulation of amyloid beta plaques in the setting of Alzheimer’s disease.

Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.  All product information available on this website is for educational purposes only.

Molecular Formula


Research literature

31436480 2020-01-01 Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist Diabetes technology & therapeutics
31185157 2019-08-29 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England journal of medicine
29915923 2018-12-01 Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist Clinical pharmacokinetics
29756388 2018-09-01 Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis Diabetes, obesity & metabolism
29766634 2018-09-01 Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Diabetes, obesity & metabolism
29205786 2018-04-01 Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment Diabetes, obesity & metabolism
29049653 2017-10-17 Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial JAMA
28266779 2017-09-01 Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Diabetes, obesity & metabolism
28323117 2017-06-15 Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
26308095 2015-09-24 Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of medicinal chemistry
24608440 2014-07-01 The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates Diabetes
5316 1975-09-01 [Effect of electrolytes on the extraction of coniine, phenatin, cyclodol and tropacine by organic solvents] Farmatsiia


There are no reviews yet.

Be the first to review “Semaglutide 2 mg GLP-1 analogue peptide – diabetes, weight loss research”
SuperhumanStore - longevity, dutasteride mesotherapy, NAD+, peptides, Cerebrolysin, exosomes, anti-aging, senolytics
    Your Cart
    Your cart is emptyReturn to Shop